Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: Results from the multicenter X-sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study

Gregg W. Stone, David A. Cox, Reginald Low, Christopher U. Cates, Lowell Satler, Steven R. Bailey, Richard E. Kuntz, Alexandra J. Lansky

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Intervention in thrombotic lesions and diseased saphenous vein grafts frequently results in thromboembolic complications, including no-reflow, distal branch occlusion, periprocedural MI, and death. The utility of a novel thromboatherectomy device, the X-Sizer, was tested in 50 consecutive patients at nine U.S. centers. A total of 61 lesions were treated in 31 vein grafts and 19 native coronary arteries; thrombus was present in 78% of lesions, and TIMI 0-1 flow in 21%. TIMI 3 flow improved from 57% at baseline to 94% postprocedure. No patient developed visible distal thromboemboli, side-branch occlusion, or reduced antegrade flow. Thirty-day events included one death (2.0%), Q- or non-Q-wave MI in 4.0%, TVR in 6.0%, and any MACE in 6.0%. We conclude that the use of the X-Sizer prior to percutaneous intervention is safe in high-risk vein grafts and thrombotic lesions and results in a low rate of adverse events compared to historical controls.

Original languageEnglish (US)
Pages (from-to)419-427
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Volume58
Issue number4
DOIs
StatePublished - Apr 1 2003

Keywords

  • Saphenous vein graft
  • Stent
  • Thrombectomy
  • Thrombus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: Results from the multicenter X-sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study'. Together they form a unique fingerprint.

  • Cite this